Publications scientifiques

Depuis le 30/04/2024

  1. Safety of Dual Orexin Receptor Antagonist Daridorexant: A Disproportionality Analysis of Publicly Available FAERS Data.
    Cicala G, Barbieri MA, Russo G, Salvo F, Spina E.
    Pharmaceuticals (Basel). 2024
  2. Resective epilepsy surgery and its impact on depression in adults: a systematic review, meta-analysis, and implications for future research.
    Hernandez Poblete N, Gay F, Salvo F, Micoulaud-Franchi JA, Bienvenu T, Coelho J, Aupy J.
    J Neurol Neurosurg Psychiatry. 2024
  3. Hexahydrocannabinol poisoning reported to French poison centres.
    Labadie M, Nardon A, Castaing N, Bragança C, Daveluy A, Gaulier JM, El Balkhi S, Grenouillet M; French Poison Centre Research Group; Christine Tournoud.
    Clin Toxicol (Phila). 2024
  4. Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network.
    Gandolfo P, Soeiro T, Jouve É, Revol B, Daveluy A, Bertin C, Eiden C, Gibaja V, Chaouachi L, Pérault-Pochat MC, Chevallier C, Aquizérate A, Le Boisselier R, Carton L, Lapeyre-Mestre M, Frauger É, Lacroix C, Micallef J.
    Fundam Clin Pharmacol. 2024
  5. Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.
    de Germay S, Pambrun E, Pariente A, Grenet G, Bezin J, Faillie JL.
    Diabetes Obes Metab. 2024
  6. What should be done to combat misinformation about health products?
    Micallef J, Maisonneuve H, Muller S, Molimard M, Bégaud B, Cabut S, Daban M, Drici MD, Gatignol C, Grumblat A, Guaspare-Cartron C, Lasserre B, Mebarki A, Pons C, Prabonnaud F, Raynaud C, Saint-Lary O.
    Therapie. 2023
  7. A successful linkage of a named patient products of sublingual immunotherapy-dispensing registry to French healthcare insurance database (SNDS): methodological constitution of the EfficAPSI cohort.
    Devillier P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Demoly P.
    Expert Rev Clin Immunol. 2023
  8. Psychoactive substance intoxication leading to general hospital admission in young and middle-aged people during and after the first lockdown.
    Perino J, Ramaroson H, Ong N, Lancelot V, Bezin J, Gilleron V, Daveluy A, Tournier M.
    Therapie. 2023
  9. Effects of iloprost in patients with critical limb ischemia: Results of a cohort study from the COPART registry.
    Dari L, Constans J, Boulon C, Caradu C, Labépie FX, Bura-Rivière A, Chastaingt L, Lacroix P, Bezin J, Pariente A.
    J Med Vasc. 2023
  10. Cost-effectiveness of screening of coronary artery disease in patients with type 2 diabetes at a very high cardiovascular risk (SCADIAB) study. Updated study design: emulation of a randomised target trial using electronic health records.
    Mohammedi K, Cordon A, Rigalleau V, Foussard N, Bairras-Martin C, Couffinhal T, Bezin J, Benard A.
    Cardiovasc Diabetol. 2023
  11. Quelles actions pour lutter contre la désinformation sur les produits de santé ?
    Micallef J, Maisonneuve H, Muller S, Molimard M, Bégaud B, Cabut S, Daban M, Drici MD, Gatignol C, Grumblat A, Guaspare-Cartron C, Lasserre B, Mebarki A, Pons C, Prabonnaud F, Raynaud C, Saint-Lary O.
    Therapie. 2023
  12. Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: A nationwide population-based cohort study.
    Allouchery M, Brunet K, Tomowiak C, Singier A, Pambrun E, Pariente A, Bezin J, Pérault-Pochat MC, Salvo F.
    Mycoses. 2023
  13. Real-world effect of iloprost in patients with chronic limb-threatening ischemia (CLTI): A cohort study.
    Loubna D, Constans J, Boulon C, Caradu C, Lapébie FX, Bura-Rivière A, Chastaingt L, Lacroix P, Bezin J, Pariente A.
    Vasc Med. 2023
  14. Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France.
    de Germay S, Singier A, Salvo F, Pariente A; French Pharmacovigilance Network.
    Drug Saf. 2023
  15. Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase.
    Calapai F, Mannucci C, McQuain L, Salvo F.
    Pharmaceuticals (Basel). 2023
  16. Analgesic switching in chronic users of dextropropoxyphene in France.
    Daveluy A, Bryan MC, Miremont-Salamé G, Lassalle R, Lacueille C, Grelaud A, Floccia M, Haramburu F, Lapeyre-Mestre M, Micallef J, Salvo F.
    Fundam Clin Pharmacol. 2023
  17. Statin treatment is not associated with an increased risk of adrenal insufficiency in real-world setting.
    Maumus-Robert S, Jarne-Munoz A, Pariente A, Duroux T, Duranteau L, Bezin J.
    Front Endocrinol (Lausanne). 2023
  18. Factors associated with internal contamination of nurses by antineoplastic drugs based on biomonitoring data from a previous study.
    Villa A, Geshkovska A, Bellagamba G, Baldi I, Molimard M, Verdun-Esquer C, Lehucher-Michel MP, Canal-Raffin M.
    Int J Hyg Environ Health. 2023
  19. Dual Orexin Receptor Antagonists and Suicide Risk: Findings From the WHO Spontaneous Reporting Database.
    Salvo F, Micoulaud-Franchi JA, Palagini L, Geoffroy PA.
    J Clin Psychiatry. 2023
  20. Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer.
    Gouverneur A, Favary C, Jové J, Rouyer M, Bignon E, Salvo F, Tchalla A, Paillaud E, Aparicio T, Noize P.
    Target Oncol. 2023